Navigation Links
New research identifies modifiable risk factors for heart disease
Date:12/11/2009

in heart function and blood vessel wall thickness at two years compared with baseline measures. Whether the present findings translate into improved clinical outcomes requires further investigation.

More Intensive Cholesterol-Lowering Drugs Appear to Outshine Standard or Moderate Statin Therapy in the Prevention of Recurrent Cardiovascular Disease in Certain Patients; Stronger Statins Prevent Not Just First Heart Problem, but Also Second and Third Heart Attack

Two studies in this issue find that use of higher strength statin medications prevent not just a first cardiac event, but also a second or third event as well showing an even greater benefit of statin therapy than previously thought.

Data from over 14,000 patients from two large randomized lipid-lowering trials the Pravastin or Atorvastatin Evaluation and Infection Therapy-Thrombosis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Incremental Decreases in End Points through Aggressive Lipid Lowering (IDEAL) trials were analyzed in a new way to count the total number of heart problems. Traditionally, trials are analyzed based on the time to first cardiovascular event and, as a result, statistical analyses did not include subsequent cardiovascular events. Results from the expanded analyses of the PROVE-IT and IDEAL data found intensive statin therapy to be more effective than standard or moderate statin therapy in preventing additional atherosclerotic development and future cardiovascular events. When additional events are considered, the total number of events prevented by more intensive lipid-lowering therapy was substantially greater.

As previously reported by PROVE-IT, first primary end point events (death, heart attack, stroke, UA requiring rehospitalization, or revascularization) were reduced by 16 percent with atorvastatin 80 mg (intensive lipid lowering) versus pravastatin 40 mg (moderate lipid lowering) (n = 464 vs. n = 537, respectively; p = 0.005). When reexami
'/>"/>

Contact: Amanda Jekowsky
ajekowsk@acc.org
202-375-6645
American College of Cardiology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... An Oregon State University researcher has found a relationship ... symptoms of autism spectrum disorder in very young children. ... first to show a direct relationship between motor skills ... gross motor skills should be included in treatment plans ... assistant professor in OSU,s College of Public Health and ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... ... University Edwardsville School of Pharmacy has been awarded -- along with the Saint ... (NIH) grant to study ways of relieving chronic pain through new approaches in treating ... ...
... Kimberly-Clark Corporation (NYSE: KMB ) has joined forces ... performance of some of its product packaging. The new ... which benefit schools and communities nationwide. , Kimberly-Clark, ... health, hygiene, and well being, and TerraCycle are now ...
... Life ... , ... 2009 -- Life Care Centers of America recently named Michael Lops as its ... Care, succeeds Sharon Coleman in the position. His appointment is based on “his extensive experience ...
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... , ROCKVILLE, Md., Nov. 2 Vanda Pharmaceuticals Inc. (Vanda) ... development and commercialization of clinical-stage products for central nervous system ... quarter ended September 30, 2009. , Vanda reported ... of 2009, compared to $12.4 million for the second quarter ...
... , Preliminary evaluation after completion of ... endpoint has been met for patients with advanced-stage, ... Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; ... company focused on endocrine therapy and oncology, today announced ...
Cached Medicine News:Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 2Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 3Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 4Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 2Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 3Health News:Lops named Life Care's New Chief Compliance Officer 2Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 2Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 4Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 5Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 6Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 7Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 8Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 9Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 10Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 11Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 12Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... CAMBRIDGE, Mass., Sept. 21, 2011 IntelligentMDx (IMDx) announced today ... test for the Abbott FDA cleared m 2000 instrument. ... detects and distinguishes the vanA and vanB ... specimens from patients at risk for colonization or infection. Detection ...
... 21, 2011 Mylan Inc. (Nasdaq: MYL ... settlement and license agreement with Hoffman La Roche Inc. ... 500 mg, USP, known generically as Capecitabine Tablets. This ... the treatment of metastatic breast and colorectal cancers. ...
Cached Medicine Technology:IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci 2Mylan Announces XELODA® Settlement and License Agreement 2
... for the detection and semi-quantitation of human ... (SLE), Western Equine Encephalitis (WEE), Eastern Equine ... group viruses. Each kit contains ten 8-well ... WEE, EEE, and CE in each well, ...
... immunofluorescent antibody ( RIFA:) test ... of human serum IgM antibodies ... (VCA). Each kit contains ten ... EBV VCA antigen, FITC IgM ...
... immunofluorescent antibody (IFA) test for the ... IgG antibodies to the detection and ... Epstein-Barr virus early antigens, both restricted ... contains ten 12-well slides, FITC conjugate, ...
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
Medicine Products: